Use this page to scan recent stories from Multiple Sclerosis Research, see the themes that keep appearing, and jump into complete story briefs.
Have a question this the place for you. Its ECTRIMS Month WHAT’S IN STORE? Late breaking results (a) Efficacy and Safety of Remibrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 REMODEL-1/-2 Trials. Prediction…this shows significant benefit in contrast to tolebrutinib and evobrutinib. Wh
Sorry just couldn’t resist it. The comment that made me do the Beatie cure of the week was “Have you seen this paper , it reverses paralysis and vison loss” I say have you seen my post about the snail and the car tyre. Now imagine a car driving on the road and it runs […]
There was an animal study cure of the week about Franincense and I said the results were a Shania ” They don’t inpressa me much” and I was taken to task to say that there was a trial. So I retort all the more reason not to do animal studies if there is human data. […]
B cell depletion kills B cells and also CD20+ T cells which are mainly CD8+/ EBV infected B cells will be targeted by CD8+ anti-viral cellls and so as the EBV lives in B cells, B cell depletion kills EBV and so you now do not need T cell to do killing so why make […]
There is some news from the MS Society https://www.mssociety.org.uk/research/latest-research/latest-research-news-and-blogs/alpha-lipoic-acid-moves-next-stage-octopus-trial Octopus is a multi arm multi stage (MAMS) adaptive trial with the aim of testing multiple drugs in phase II, then carry it forward into phase III a
We know that rituximab depletes B cells within 24 hours of treatment but with cladribine the depletion of cells is much, much slower and this will mean that people taking cladribine will accumulate more lesions waiting for effective disease control Abstract Number: 86/P415 Abstract Number: 86/P415 Efficacy and safety o
EBV causes MS is the mantra but you have to find one person with real MS that is not person infected with EBV and the causes can be a cause and maybe then the solutions are not all the same. In this paper they look at Japanese individuals and find EBV negative individuals So is […]
Yep a title that makes very little sense but this is the type of message you get when the media do science. This paper rolled across my desk and it was yet another cure of the week in the beasties and this was all about frankincense. Frankinsense is a smelly resin obtained from the juice […]
Prof G and the gang started the think hand campaign to use it as an outcome in progressive MS trials so that no one should be forgotten when they legs have accumulated damage and this is part of the base for Chariot-MS a trial looking at people treated with cladribine in the hope that it […]
Sound like time for MS base to get involved and sort this out as a matter Patel MA, Punnen TG, Shan KS, McCreary MC, Wright CM, Munoz SB, Hardeman P, Burgess KW, Greenberg BM, Horton LA, Sguigna PV, Tardo LM, Stüve O, Okuda DT. Clinical and radiological outcomes of directed treatment transitions from Gilenya® to […]
Okuda DT, Anderson BJ, Taylor SM, Jones-McCreary MC, Burgess KW, Wright CM, Santoyo JR, Sguigna PV, Stüve O, Tran DH, Light DY, Moog TM, Punnen TG. Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis. Clin Immunol. 202
We have a paper on “Trial of the Year from the JAMA Editor”….A bit of back patting I guess….but I find it abit weird that you do this for a trial that failed. They asked Can patients with multiple sclerosis (MS) safely discontinue their disease-modifying therapy, even after years of clinical stability? That is the […]
Open the app view when you want faster scanning, saved stories, and source-focused reading in one place.